Both in Pharmaceuticals
Immuneering vs Standard BioTools
Over the past year IMRX returned −43.9% and LAB returned −50.7%; their daily moves had a correlation of -0.09.
IMRX −43.9% LAB −50.7%Growth of $1, one year, split-adjusted
| Metric | IMRX | LAB |
|---|---|---|
| Price | $3.68 | $0.6108 |
| Market cap | $238.3M | $241.1M |
| Today | +5.44% | +0.15% |
| 1 month | −8.9% | −19.9% |
| 6 months | −31.1% | −37.6% |
| Year to date | −44.1% | −52.3% |
| 1 year | −46.4% | −49.1% |
| Revenue growth (YoY) | — | −7.6% |
| Gross margin | — | 52.4% |
| Net margin | — | −133.1% |
| P/E (TTM) | — | 2.8× |
| Price / sales | — | 2.8× |
| Net cash | $145.4M | $476.4M |
| Dividend yield | — | — |
| Volatility (60d) | 53.8% | 45.5% |
| Short % of float | 29.2% | 1.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).